| Program | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
|---|---|---|---|---|---|---|
| GATTEX (teduglutide) | Short Bowel Syndrome | |||||
| NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) | Hypoparathyroidism | |||||
| PREOS (parathyroid hormone 1-84 [rDNA origin] injection)1 | Osteoporosis1 | |||||
| Teduglutide1 | Crohn's Disease1 | |||||
| Glycine reuptake inhibitors1 | CNS1 | |||||
| Teduglutide | Pediatric Indications | |||||
| Teduglutide | GI Mucositis | |||||
| NPSP1561 | CNS1 |
| 1 | This indication is outside of our core focus and has been designated as an out-licensing or partnering opportunity. |